Sanofi Q3 Surge Drives FY 26 Outlook to Record GrowthSanofi’s Q3 surge fuels a new‑high FY‑26 outlook, driven by Dupixent growth, sharp EPS gains, and a disciplined specialty‑drug focus.SANOFI Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 30/10/2026, 08:24 3 minutes to read
